Health of Chinese healthcare supplies called into question — Panjiva
MENU

Panjiva_research_logo

Health of Chinese healthcare supplies called into question

China 2205 Health Care 145 U.S. 3973

Concerns have been raised by President Trump’s chief trade advisor, Peter Navarro, regarding the reliability of Chinese healthcare product supplies to the U.S. in light of the spread of COVID-19 coronavirus. China only supplied 1.2% of America’s $132.2 billion of pharmaceuticals and healthcare imports in 2019. Growth in those shipments of 2.1% year over year lagged the 10.9% expansion in total imports. Specific products are more exposed – for example China represented almost all U.S. laparotomy sponge imports and 43.1% of heparin. Options for action against Chinese healthcare suppliers i...

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2020 S&P Global. All Rights Reserved.